Coronavirus - we're here to help
From how to access your account online, scam awareness, your wellbeing and our community we're here to help.

Skip to main content
  • Register
  • Help
  • Contact us
  • Log in to HL Account

Vericel Corp (VCEL) Common Stock NPV

Sell:$39.50 Buy:$49.00 Change: $1.76 (4.14%)
Market closed |  Prices as at close on 8 March 2021 | Switch to live prices |
Sell:$39.50
Buy:$49.00
Change: $1.76 (4.14%)
Market closed |  Prices as at close on 8 March 2021 | Switch to live prices |
Sell:$39.50
Buy:$49.00
Change: $1.76 (4.14%)
Market closed |  Prices as at close on 8 March 2021 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Vericel Corporation is an integrated, commercial-stage biopharmaceutical company dedicated to the identification, development and commercialization of therapies that enable the body to repair and regenerate damaged tissues and organs to restore normal structure and function. The Company operates through the research, product development, manufacture and distribution of cellular therapies for use in the treatment of specific diseases.. Its autologous cell therapy products include Epicel (cultured epidermal autografts), which is a permanent skin replacement for the treatment of patients with deep-dermal or full-thickness burns. The Company is developing MACI, which is a third-generation autologous chondrocyte implant and ixmyelocel-T, which is a patient-specific multicellular therapy.

Contact details

Address:
64 Sidney St
CAMBRIDGE
02139-4170
United States
Telephone:
+1 (734) 9305555
Website:
https://vcel.com/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
VCEL
ISIN:
US92346J1088
Market cap:
$1.95 billion
Shares in issue:
45.95 million
Sector:
Biotechnology
Exchange:
NASDAQ
Country:
United States
Currency:
US dollar
Indices:
n/a

Key personnel

  • Robert Zerbe
    Independent Chairman of the Board
  • Dominick Colangelo
    President, Chief Executive Officer, Director
  • Joseph Mara
    Principal Financial Officer, Treasurer
  • Michael Halpin
    Chief Operating Officer
  • Sandra Pennell
    Principal Accounting Officer, Vice President, Controller

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.